IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovaci√≥ Tecnol√≥gica”.